ArticleProceedings of the National Academy of Sciences of the United States of America2025
T cell receptor specificity landscape revealed through de novo peptide design.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Protein persulfidation in plants: a central regulator of multiple signaling pathways.Plant cell reports · 2026Review
- Structure-based TCR-pMHC binding prediction and generalization to unseen peptides.npj drug discovery · 2026Article
- What Does the Shape Space of T Cell Epitopes Look Like?Immunological reviews · 2026Review
- Highlight of 2025: From binding prediction to molecular design-computational advances in TCR-pMHC prediction and targeting.Immunology and cell biology · 2026Review
- Technical review of artificial intelligence in TCR-T therapy.Journal of the National Cancer Center · 2026Review
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- TCRBinder: Unified pre-trained language model with paired-chain synergy for predicting T-cell receptor binding specificity.PLoS computational biology · 2026Article
- PMGen: from peptide-MHC structure prediction to peptide generation.Bioinformatics (Oxford, England) · 2026Article
- Advances in predicting T cell epitope recognition for cancer immunotherapy.Nature cancer · 2026Review
- Design principles of the cytotoxic CD8Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- HERMES: Holographic Equivariant neuRal network model for Mutational Effect and Stability prediction.bioRxiv : the preprint server for biology · 2026Article
- ProTCR: a protein language model-driven framework for decoding TCR-antigen recognition toward precision immunotherapies.Briefings in bioinformatics · 2026Article
- A Reproducible Sequence-Level Strategy to Enhance Peptide Immunogenicity While Preserving Wild-Type Epitope Recognition.Antibodies (Basel, Switzerland) · 2025Article
Corrections and comments
- Update of
- Update of
Authors and funding
6 authors.
Funding
Abstract
T cells play a key role in adaptive immunity by mounting specific responses against diverse pathogens. Effective bindings between T cell receptors (TCRs) and pathogen derived peptides presented on major histocompatibility complexes (MHCs) mediate immune responses. However, predicting these interactions remains challenging due to limited functional data on T cell reactivities. Here, we introduce a computational approach to predict TCR interactions with peptides presented on MHC-I alleles, and to design immunogenic peptides for specified TCR-MHC complexes. Our method leverages HERMES, a structure-based machine learning model trained on the protein universe to predict amino acid preferences based on local structural environments. Despite no direct training on TCR-pMHC data, HERMES's implicit physical reasoning enables us to make accurate predictions of both TCR-pMHC binding affinities and T cell activities across diverse viral and cancer epitopes, achieving up to 0.72 correlation with experimental data. Leveraging our TCR recognition model, we develop a computational protocol for de novo design of immunogenic peptides. Through experimental validation in three TCR-MHC systems, we demonstrate that our designs-with up to five substitutions from the native sequence-activate T cells at success rates of up to 50%. Last, we use our generative framework to quantify the diversity of the peptide recognition landscape for various TCR-MHC's, offering key insights into T cell specificity. Our approach provides a platform for immunogenic peptide and neoantigen design, as well as for evaluating TCR specificity, offering a computational framework to inform design of engineered T cell therapies and vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.